BLCM stock forecast
Our latest prediction for Bellicum Pharmaceuticals, Inc.'s stock price was made on the Sept. 10, 2019 when the stock price was at 1.27$.
In the short term (2weeks), BLCM's stock price should outperform the market by 7.32%. During that period the price should oscillate between -7.63% and +17.76%.
In the medium term (3months), BLCM's stock price should outperform the market by 14.98%. During that period the price should oscillate between -16.92% and +44.80%.Get email alerts
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
At the moment the company generates 3M USD in revenues.
On its last earning announcement, the company reported a loss of -2.31$ per share.
The book value per share is 2.60$
Three months stock forecastSept. 10, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|